Composition, form of production and packaging
Tablets are almost white or white with a creamy shade of color, flat-cylindrical, with a facet and a risk.
1 tab.
betahistine dihydrochloride 8 mg
[PRING] cellulose microcrystalline - 54.75 mg, povidone (kollidon 25) - 9 mg, potato starch - 20 mg, citric acid - 2 mg, silicon dioxide colloid (aerosil) - 3 mg, talc - 2.8 mg, magnesium stearate - 0.45 mg .
10 pieces. - packings of cellular planimetric (3, 5) - packs cardboard.
30 pcs. - packings of cellular contour (1, 2, 3) - packs cardboard.
30 pcs. - polymer cans (1) - packs of cardboard.
Tablets are almost white or white with a creamy shade of color, flat-cylindrical, with a facet and a risk.
1 tab.
betahistine dihydrochloride 16 mg
[PRING] cellulose microcrystalline - 109.5 mg, povidone (kollidon 25) - 18 mg, potato starch - 40 mg, citric acid - 4 mg, silicon dioxide colloid (aerosil) - 6 mg, talc - 5.6 mg, magnesium stearate - 0.9 mg .
10 pieces. - packings of cellular planimetric (3, 5) - packs cardboard.
30 pcs. - packings of cellular contour (1, 2, 3) - packs cardboard.
30 pcs. - polymer cans (1) - packs of cardboard.
Tablets are almost white or white with a creamy shade of color, flat-cylindrical, with a facet and a risk.
1 tab.
betahistine dihydrochloride 24 mg
[PRING] microcrystalline cellulose - 164.25 mg, povidone (kollidon 25) - 27 mg, potato starch - 60 mg, citric acid - 6 mg, silicon dioxide colloid (aerosil) - 9 mg, talc - 8.4 mg, magnesium stearate - 1.35 mg .
10 pieces. - packings of cellular planimetric (3, 5) - packs cardboard.
30 pcs. - packings of cellular contour (1, 2, 3) - packs cardboard.
30 pcs. - polymer cans (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
A drug that improves the microcirculation of the labyrinth, used in the pathology of the vestibular apparatus. Betagistin acts mainly on the histamine H 1 - and H 3receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic action on histamine H 1 -receptors of the vessels of the inner ear, and also indirectly through the action on histamine H 3 -receptors improves microcirculation and permeability of capillaries, normalizes the pressure of the endolymph in the labyrinth and cochlea. At the same time, betagistin increases blood flow in the basilar artery.
Has a pronounced central effect, being an inhibitor of histamine H3 receptors in the nuclei of the vestibular nerve. Normalizes the conductivity in the neurons of the vestibular nuclei at the level of the brainstem.
The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in noise in the ears, and improvement in hearing in the event of a decrease in it.
PHARMACOKINETICS
Suction and distribution
Absorbed quickly. T max - 3 h. Binding to plasma proteins is low.
Metabolism and excretion
It is almost completely excreted by the kidneys in the form of a metabolite (2-pyridylacetic acid) for 24 hours. T 1/2 - 3-4 hours.
INDICATIONS
- treatment and prevention of vestibular vertigo of various origin;
- Syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;
- illness or Meniere's syndrome.
DOSING MODE
The drug is administered orally, with meals.
Tablets 8 mg - for 1-2 tablets. 3 times / day.
Tablets of 16 mg - on 1/2 - 1 tab. 3 times / day.
Tablets of 24 mg - 1 tab. 2 times / day.
Improvement is usually noted already at the beginning of therapy, a stable therapeutic effect occurs after two weeks of treatment and may increase over several months of treatment. Treatment is long. The duration of treatment is determined individually.
SIDE EFFECT
Possible: gastrointestinal disorders, reactions of hypersensitivity (rash, itching, urticaria), Quincke's edema.
CONTRAINDICATIONS
- age under 18 years (due to lack of data);
- Pregnancy (due to lack of data);
- lactation period (due to lack of data);
- Hypersensitivity to any of the components of the drug.
With caution should prescribe the drug with peptic ulcer of the stomach and duodenum (including in the anamnesis), pheochromocytoma, bronchial asthma. These patients should be observed regularly during the treatment period.
PREGNANCY AND LACTATION
Due to the lack of data, the drug is contraindicated in pregnancy and lactation.
APPLICATION FOR CHILDREN
Contraindication: age under 18 years (due to lack of data).
SPECIAL INSTRUCTIONS
Impact on the ability to drive vehicles and manage mechanisms
Betagistin has no sedative effect and does not affect the ability to drive a car or engage in activities requiring rapidity of psychomotor reactions.
OVERDOSE
Symptoms: nausea, vomiting, convulsions.
Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.
DRUG INTERACTION
Cases of interaction or incompatibility with other drugs are unknown.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored out of reach of children, dry, protected from light, at a temperature of no higher than 25 В° C. Shelf life - 3 years. Do not use after the expiration date stated on the package.
